Isoniazid resistance among tuberculosis patients by birth cohort in Germany

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 10, 2003, Pages 973-979

  Forssbohm, Michael ^a,b,d   Loddenkemper, R ^b   Rieder, H L ^c  

^a Public Health Authority   (Germany)

^b Ger Ctrl Comm against TB (DZK)   (Germany)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d Gesundheitsamt Wiesbaden   (Germany)

Author keywords

Drug resistance; Germany; Isoniazid; Surveillance; Tuberculosis

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; GERMANY; HEALTH CARE POLICY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; ISONIAZID; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 0141894839     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
2. Schwoebel V, Lambregts-van Weezenbeek C S B, Moro M L, et al. Standardization of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Lung Disease (IUATLD) Working Group. Eur Respir J 2000; 16: 364-371.
3. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. 23. Informationsbericht. Deutsches Zentralkomitee 1997; 1-110.
4. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. 24. Informationsbericht. Deutsches Zentralkomitee 1998; 1-111.
5. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. Tuberkulose in Deutschland 1998. 25. Informationsbericht. D Z K 1999; 25: 1-111.
6. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. 26. Informationsbericht. Deutsches Zentralkomitee 2001; 1-112.
7. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. 27. Informationsbericht. Deutsches Zentralkomitee zur Bekkämpfung der Tuberkulose, Berlin, 2002; pp. 1-112.
8. Pablos-Méndez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
9. Rieder H L. Epidemiology of tuberculosis in children. Ann Nestlé 1997; 55: 1-9.
10. Kimerling M E, Vaughn E S, Dunlap N E. Childhood tuberculosis in Alabama: epidemiology of disease and indicators of program effectiveness, 1983 to 1993. Pediatr Infect Dis J 1995; 14: 678-684.
11. Rieder H L. Drug-resistant tuberculosis: issues in epidemiology and challenges for public health. Tubercle Lung Dis 1994; 75: 321-323.
12. van Soolingen D, Borgdorff M W, de Haas P E W, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180: 726-736.
13. Castro K G, Jaffe H W. Rationale and methods for the national tuberculosis genotyping and surveillance network. Emerging Infect Dis 2002; 8: 1188-1191.
14. Desemone J, Opila D A. Elevated carcinoembryonic antigen in tuberculous pericarditis. (Correspondence). N Y State J Med 2002; November: 544.
15. Sutherland I, Švandová, E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model of clinical tuberculosis following infection, linking data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 1982; 63: 255-268.
16. Bloch A B, Cauthen G M, Onorato I M, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-671.
17. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
18. Li Z, Kelley C, Collins F, Rouse D, Morris S. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 1998; 177: 1030-1035.
19. Wilson T M, De Lisle G W, Collins D M. Effect of inbA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 1995; 15: 1009-1015.
20. Müller H. AIDS und Tuberkulose - die Situation in Köln. [Editorial] Oeff Gesundh - Wes 1991; 53: 23-25.
21. Forssbohm M, Schempp R, Valenteijn A. HIV-Infektion bei Tuberkulosepatienten in Frankfurt/Main 1982-1989. Atemw-Lungenkrkh 1991; 1: 31-38.
22. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. Richtlinien zur medikamentösen Behandlung der Tuberkulose im Erwachsenen-und Kindesalter. Pneumologie 2001; 55: 494-511.
23. EuroTB (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 1999. EuroTB 2002; 1-117.
24. Rieder H L, Zellweger J P, Raviglione M C, Keizer S T, Migliori G B. Tuberculosis control in Europe and international migration. Report of a European Task Force. Eur Respir J 1994; 7: 1545-1553.
25. Migliori G B, Raviglione M C, Schaberg T, et al. Tuberculosis management in Europe. Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 1999; 14: 978-992.